Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Whyte

Endocrinology, Diabetes & Metabolism Saint Louis, MO Medical Doctor

NPI 1235168071 CMS profile 237788

4921 Parkview Pl, Div Im Bone & Mineral, Ste 5C, Saint Louis, MO 63110

Open in the dashboard

General payments

$40,284

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$92,704 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Michael Whyte of Saint Louis, MO is reported in the CMS Open Payments database as having received $40,284 across 50 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $92,704 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,204 13
2024 General $7,350 13
2023 General $7,527 13
2022 General $5,490 1
2020 General $1,500 1
2019 General $8,213 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Whyte
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michael Whyte were reported at $10,204. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michael Whyte Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $8,213 $494 $123–$2,253 $163
2020 $1,500 $335 $85–$1,841 $114
2021 $0 $398 $88–$1,981 $132
2022 $5,490 $364 $88–$1,568 $149
2023 $7,527 $420 $113–$1,614 $160
2024 $7,350 $440 $121–$1,646 $164
2025 $10,204 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kyowa Kirin, Inc. $24,351 35 payments
  2. Daiichi Sankyo Inc. $8,090 8 payments
  3. Ultragenyx Pharmaceutical Inc. $6,990 2 payments
  4. Novo Nordisk Health Care AG $405 1 payment
  5. Radius Health, Inc. $123 1 payment
  6. Amgen Inc. $116 1 payment
  7. Ascendis Pharma, Inc. $108 1 payment
  8. Dentsply Sirona Orthodontics Inc $101 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,955 10 payments
  2. Travel and Lodging $4,511 14 payments
  3. Food and Beverage $1,818 26 payments
Products named General payments · program years 2019–2025
  1. CRYSVITA Fibroblast Growth Factor 23 Fgf23 Blocking Antibody $10,204 13 payments
  2. Crysvita fibroblast growth factor 23 (FGF23) blocking antibody. $6,829 11 payments
  3. Crysvita XLH Metabolic Bone Disorder $5,490 1 payment
  4. Cryvista $1,500 1 payment
  5. Tymlos $123 1 payment
  6. SureSmile $101 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record